|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
2
|
Gorlick R and Khanna C: Osteosarcoma. J
Bone Miner Res. 25:683–691. 2010. View
Article : Google Scholar
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clevers H: The cancer stem cell: premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li L and Neaves WB: Normal stem cells and
cancer stem cells: the niche matters. Cancer Res. 66:4553–4557.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maitland NJ and Collins AT: Prostate
cancer stem cells: a new target for therapy. J Clin Oncol.
26:2862–2870. 2008. View Article : Google Scholar
|
|
8
|
Di Fiore R, Santulli A, Ferrante RD,
Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere
G and Vento R: Identification and expansion of human
osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide
treatment. J Cell Physiol. 219:301–313. 2009.PubMed/NCBI
|
|
9
|
Di Fiore R, Drago-Ferrante R, D’Anneo A,
De Blasio A, Santulli A, Messina C, Carlisi D, Tesoriere G and
Vento R: Differentiation of human osteosarcoma 3AB-OS stem-like
cells in derivatives of the three primary germ layers as an useful
in vitro model to develop several purposes. Stem Cell Discov.
3:188–201. 2013.
|
|
10
|
Di Fiore R, Guercio A, Puleio R, Di Marco
P, Drago-Ferrante R, D’Anneo A, De Blasio A, Carlisi D, Di Bella S,
Pentimalli F, Forte IM, Giordano A, Tesoriere G and Vento R:
Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell
xenografts. J Cell Biochem. 113:3380–3392. 2012.PubMed/NCBI
|
|
11
|
Di Fiore R, Fanale D, Drago-Ferrante R,
Chiaradonna F, Giuliano M, De Blasio A, Amodeo V, Corsini LR, Bazan
V, Tesoriere G, Vento R and Russo A: Genetic and molecular
characterization of the human osteosarcoma 3AB-OS cancer stem cell
line: a possible model for studying osteosarcoma origin and
stemness. J Cell Physiol. 228:1189–1201. 2013.PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression
profiles classify human cancers. Nature. 435:834–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M,
Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M,
Harris CC and Croce CM: A microRNA expression signature of human
solid tumors defines cancer gene targets. Proc Natl Acad Sci USA.
103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hatfield S and Ruohola-Baker H: microRNA
and stem cell function. Cell Tissue Res. 331:57–66. 2008.
View Article : Google Scholar
|
|
17
|
Hatfield SD, Shcherbata HR, Fischer KA,
Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is
regulated by the microRNA pathway. Nature. 435:974–978. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang B, Pan X and Anderson TA: MicroRNA:
a new player in stem cells. J Cell Physiol. 209:266–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ibarra I, Erlich Y, Muthuswamy SK,
Sachidanandam R and Hannon GJ: A role for microRNAs in maintenance
of mouse mammary epithelial progenitor cells. Genes Dev.
21:3238–3243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates
self renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maire G, Martin JW, Yoshimoto M,
Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of
miRNA-gene expression-genomic profiles reveals complex mechanisms
of microRNA deregulation in osteosarcoma. Cancer Genet.
204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lulla RR, Costa FF, Bischof JM, Chou PM,
de Bonaldo FM, Vanin EF and Soares MB: Identification of
differentially expressed microRNAs in osteosarcoma. Sarcoma.
2011:7326902011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL,
Volinia S, Stein GS, Croce CM, Lian JB and Aqeilan RI: miRNA
signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang W, Qian JX, Yi HL, Yang ZD, Wang CF,
Chen JY, Wei XZ, Fu Q and Ma H: The microRNA-29 plays a central
role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk).
46:622–627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Di Fiore R, Marcatti M, Drago-Ferrante R,
D’Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore
L, Tesoriere G and Vento R: Mutant p53 gain of function can be at
the root of dedifferentiation of human osteosarcoma MG63 cells into
3AB-OS cancer stem cells. Bone. 60:198–212. 2014.PubMed/NCBI
|
|
26
|
Gawrychowski J, Lackowska B and Gabriel A:
Prognosis of the surgical treatment of patients with non-small cell
lung cancer (NSCLC) - relation to DNA ploidy. Eur J Cardiothorac
Surg. 23:870–877. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK
and Fine HA: Tumor stem cells derived from glioblastomas cultured
in bFGF and EGF more closely mirror the phenotype and genotype of
primary tumors than do serum-cultured cell lines. Cancer Cell.
9:391–403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side
population is enriched in tumorigenic, stem-like cancer cells,
whereas ABCG2+ and ABCG2− cancer cells are
similarly tumorigenic. Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone
sarcomas contain CD133+ cancer stem cells displaying
high tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li
JM, Yang T and Liu W: CD133 expression in osteosarcoma and
derivation of CD133+ cells. Mol Med Rep. 7:577–584.
2013.PubMed/NCBI
|
|
31
|
Pompetti F, Rizzo P, Simon RM, Freidlin B,
Mew DJ, Pass HI, Picci P, Levine AS and Carbone M: Oncogene
alterations in primary, recurrent, and metastatic human bone
tumors. J Cell Biochem. 63:37–50. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuijjer ML, Rydbeck H, Kresse SH, Buddingh
EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC,
Meza-Zepeda LA and Cleton-Jansen AM: Identification of osteosarcoma
driver genes by integrative analysis of copy number and gene
expression data. Genes Chromosomes Cancer. 51:696–706. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kresse SH, Rydbeck H, Skårn M, Namløs HM,
Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K,
Hogendoorn PC, Hovig E, Myklebost O and Meza-Zepeda LA: Integrative
analysis reveals relationships of genetic and epigenetic
alterations in osteosarcoma. PLoS One. 7:e482622012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pösl M, Amling M, Werner M, Bäsler I,
Salzer-Kuntschik M, Winkler K and Delling G: Osteosarcoma -
apoptosis and proliferation. Study of bcl-2 expression. Pathologe.
15:337–344. 1994.PubMed/NCBI
|
|
35
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expression of p53, BCL-2, and apoptotic index in human osteosarcoma
and their correlation with prognosis of patients. Cancer Epidemiol.
36:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: how many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogawa H, Ishiguro K, Gaubatz S, Livingston
DM and Nakatani Y: A complex with chromatin modifiers that occupies
E2F- and Myc-responsive genes in G0 cells. Science. 296:1132–1136.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang
C, Wang Y, Luo M, Zhao H, Dong L, Song W, Wang F, Wang W, Zhang J
and Yu J: Characterization of microRNA-29 family expression and
investigation of their mechanistic roles in gastric cancer.
Carcinogenesis. 35:497–506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li L, Sarver AL, Alamgir S and Subramanian
S: Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3
and CCND2 expression in rhabdomyosarcoma. Lab Invest. 92:571–583.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dimova DK and Dyson NJ: The E2F
transcriptional network: old acquaintances with new faces.
Oncogene. 24:2810–2826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen C and Wells AD: Comparative analysis
of E2F family member oncogenic activity. PLoS One. 2:e9122007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vidal A and Koff A: Cell-cycle inhibitors:
three families united by a common cause. Gene. 247:1–15. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hoang BH, Kubo T, Healey JH, Yang R,
Nathan SS, Kolb EA, Mazza BA, Meyers PA and Gorlick R: 2004
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma
cells by modulating the Wnt-β-catenin pathway. Cancer Res.
64:2734–2739. 2004.PubMed/NCBI
|
|
45
|
Shiratsuchi H, Nakashima T, Hirakawa N,
Toh S, Nakagawa T, Saito T, Tsuneyoshi M and Komune S: beta-Catenin
nuclear accumulation in head and neck mucoepidermoid carcinoma: Its
role in cyclin D1 overexpression and tumor progression. Head Neck.
29:577–584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ohira M, Oba S, Nakamura Y, Hirata T,
Ishii S and Nakagawara A: A review of DNA microarray analysis of
human neuroblastomas. Cancer Lett. 228:5–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kessler JD, Hasegawa H, Brun SN,
Emmenegger BA, Yang ZJ, Dutton JW, Wang F and Wechsler-Reya RJ:
N-myc alters the fate of preneoplastic cells in a mouse model of
medulloblastoma. Genes Dev. 23:157–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Okita K, Ichisaka T and Yamanaka S:
Generation of germline-competent induced pluripotent stem cells.
Nature. 448:313–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
de Almagro MC and Vucic D: The inhibitor
of apoptosis (IAP) proteins are critical regulators of signaling
pathways and targets for anti-cancer therapy. Exp Oncol.
34:200–211. 2012.PubMed/NCBI
|
|
52
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorigenicity, and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
53
|
Ru P, Steele R, Newhall P, Phillips NJ,
Toth K and Ray RB: miRNA-29b suppresses prostate cancer metastasis
by regulating epithelial-mesenchymal transition signaling. Mol
Cancer Ther. 11:1166–1173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gebeshuber CA, Zatloukal K and Martinez J:
miR-29a suppresses tristetraprolin, which is a regulator of
epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009.
View Article : Google Scholar : PubMed/NCBI
|
